Page last updated: 2024-10-20

pyridoxamine and Liver Cirrhosis

pyridoxamine has been researched along with Liver Cirrhosis in 1 studies

Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.

Research Excerpts

ExcerptRelevanceReference
"Thioacetamide treatment resulted in hepatic dysfunction manifested by increased serum levels of bilirubin, gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT), and aspartate aminotransferase (AST)."1.72A promising antifibrotic drug, pyridoxamine attenuates thioacetamide-induced liver fibrosis by combating oxidative stress, advanced glycation end products, and balancing matrix metalloproteinases. ( Alharbi, FM; Alhusaini, AM; Alshanwani, AR; Arafah, MM; Badr, AM; Faddah, LM; Fayed, A; Hagar, H; Shaheen, S; Sharma, AK, 2022)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Alshanwani, AR1
Hagar, H1
Shaheen, S1
Alhusaini, AM1
Arafah, MM1
Faddah, LM1
Alharbi, FM1
Sharma, AK1
Fayed, A1
Badr, AM1

Other Studies

1 other study available for pyridoxamine and Liver Cirrhosis

ArticleYear
A promising antifibrotic drug, pyridoxamine attenuates thioacetamide-induced liver fibrosis by combating oxidative stress, advanced glycation end products, and balancing matrix metalloproteinases.
    European journal of pharmacology, 2022, May-15, Volume: 923

    Topics: Animals; Glycation End Products, Advanced; Liver; Liver Cirrhosis; Matrix Metalloproteinase 2; Matri

2022